AxoGen, Inc. (NASDAQ:AXGN - Get Free Report) hit a new 52-week high on Monday . The stock traded as high as $16.48 and last traded at $15.86, with a volume of 167847 shares traded. The stock had previously closed at $15.64.
Analyst Ratings Changes
Separately, StockNews.com raised shares of AxoGen from a "hold" rating to a "buy" rating in a research note on Tuesday, October 15th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and an average price target of $15.00.
View Our Latest Analysis on AXGN
AxoGen Stock Performance
The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.47 and a current ratio of 3.74. The firm has a market capitalization of $756.50 million, a price-to-earnings ratio of -53.72 and a beta of 1.06. The firm's 50 day simple moving average is $13.97 and its 200 day simple moving average is $11.85.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in AXGN. First Light Asset Management LLC raised its stake in AxoGen by 336.6% in the 2nd quarter. First Light Asset Management LLC now owns 3,344,033 shares of the medical equipment provider's stock valued at $24,211,000 after purchasing an additional 2,578,147 shares during the last quarter. Divisadero Street Capital Management LP raised its position in shares of AxoGen by 587.2% in the second quarter. Divisadero Street Capital Management LP now owns 686,994 shares of the medical equipment provider's stock valued at $4,974,000 after buying an additional 587,024 shares during the last quarter. Parkman Healthcare Partners LLC purchased a new position in shares of AxoGen in the third quarter worth about $5,789,000. FMR LLC boosted its position in AxoGen by 743.1% during the third quarter. FMR LLC now owns 178,957 shares of the medical equipment provider's stock worth $2,509,000 after acquiring an additional 157,730 shares during the last quarter. Finally, Eagle Asset Management Inc. purchased a new stake in AxoGen during the 3rd quarter valued at about $1,728,000. Hedge funds and other institutional investors own 80.29% of the company's stock.
About AxoGen
(
Get Free Report)
AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.
Featured Articles
Before you consider AxoGen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AxoGen wasn't on the list.
While AxoGen currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
